. 2010 Aug 17;2:101–119. doi: 10.2147/DHPS.S6317

Table 10.

The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with tocilizumab monotherapy and in combination with methotrexate or DMARD. Tocilizumab groups received 8 mg/kg every 4 weeks

	CHARISMA63			OPTION64		TOWARD65		RADIATE66
	MTX + placebo n = 49	TCZ n = 52	MTX + TCZ n = 50	MTX + placebo n = 204	MTX + TCZ n = 205	DMARD + placebo n = 415	DMARD + TCZ n = 805	MTX + placebo n = 160	MTX + TCZ n = 175
20–24 wks (%):
ACR 20	41	63	74^a	26	59^a	25	61^a	10	50^a
ACR 50	29	41	53	11	44^a	9	38^a	4	29^a
ACR 70	16	16	37	2	22^a	3	21^a	1	12^a

Note:

P < 0.001 compared to placebo.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; TCZ, tocilizumab.